Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019–2020 influenza seasonYong Chong, Hideyuki Ikematsu, Naoki Kawai et al.|Antiviral Research|2021Cited by 16
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 seasonTakeyuki Goto, Hideyuki Ikematsu, Naoki Kawai et al.|Antiviral Research|2024Cited by 9
Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 SeasonTakeyuki Goto, Hideyuki Ikematsu, Naoki Kawai et al.|Influenza and Other Respiratory Viruses|2024Cited by 5
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasonsNaoki Tani, Seizaburo Kashiwagi, Naoki Kawai et al.|Journal of Infection and Chemotherapy|2022Cited by 3
Duration of fever and other symptoms after laninamivir octanoate hydrate inhalation over eight influenza seasonsNaoki Tani, Seizaburo Kashiwagi, Naoki Kawai et al.|Unknown|2020Cited by 0